biostudies-literatureUnknown29(12)Do DV<h4>Purpose</h4>To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME) and a central subfield thickness (CFT) of ≥250 μm on time-domain optical coherence tomography.DesignRandomized, controlled, multicenter clinical trial.<h4>Methods</h4>Eligible eyes were randomized in a 1:1 ratio to 0.5 mg (n=77) or 2.0 mg (n=75) RBZ. Study eyes received 6-monthly injections.Main outcome measuresThe primary outcome measure was the mean change in best corrected visual acuity (BCVA) at month 6. Secondary outcomes included the incidence and severity of systemic and ocular adverse events and the mean change in CFT from baseline.<h4>Results</h4>In all, 152 eyes (152 patients) were randomized in the study. At month 6, the mean improvement from Eye (London, England)1538-44https://www.ebi.ac.uk/biostudies/studies/S-EPMC5129796biostudies-literatureMonth-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).PMC5129796Pollack JZhang KWilson DJMarcus DMCiscato BCrocker MSadiq MARego KCallanan DGMarcus DSepah YJRajagopalan NREAD-3 Study GroupLopez JMaya JAbraham PAgarwal ADo DVYuhas PSarwar SConway BPBothwell RBoyer DLash SGreen BNguyen QDChen LKruger EBennett MTam AFoster ASymons ASoliman MKCampochiaro PAGreer LCallanan DGallemore RBelz JHalperin LLit ERenslow SHanout MfalseMonth-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).<h4>Purpose</h4>To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME) and a central subfield thickness (CFT) of ≥250 μm on time-domain optical coherence tomography.DesignRandomized, controlled, multicenter clinical trial.<h4>Methods</h4>Eligible eyes were randomized in a 1:1 ratio to 0.5 mg (n=77) or 2.0 mg (n=75) RBZ. Study eyes received 6-monthly injections.Main outcome measuresThe primary outcome measure was the mean change in best corrected visual acuity (BCVA) at month 6. Secondary outcomes included the incidence and severity of systemic and ocular adverse events and the mean change in CFT from baseline.<h4>Results</h4>In all, 152 eyes (152 patients) were randomized in the study. At month 6, the mean improvement from 2015-01-01T00:00:00Z2015 Dec2025-04-04T20:24:06.594Z2019-03-27T02:30:14ZS-EPMC51297962622829110.1038/eye.2015.142